Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹106Cr
Rev Gr TTM
Revenue Growth TTM
41.19%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

AMBANIORGO
VS
| Quarter | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | -16.0 | -30.8 | 71.8 | 156.4 | -3.8 | -0.6 | 12.8 | -6.1 | 12.4 | 31.5 | 49.7 | 33.5 |
| 33 | 24 | 57 | 64 | 55 | 64 | 61 | 58 | 76 | 77 | 106 | 103 |
Operating Profit Operating ProfitCr |
| 6.8 | 8.6 | 5.9 | 4.3 | 5.8 | 3.8 | 7.1 | 7.1 | -3.3 | 5.2 | 4.6 | 6.0 |
Other Income Other IncomeCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 |
Interest Expense Interest ExpenseCr | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 3 | 5 |
Depreciation DepreciationCr | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| 2 | 1 | 3 | 2 | 2 | 2 | 3 | 2 | 1 | 0 | 3 | 3 |
| 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | -3 | 0 | 1 | 2 |
|
Growth YoY PAT Growth YoY% | -13.2 | -38.3 | 37.0 | 100.0 | -2.4 | 12.2 | -12.2 | -86.8 | 171.3 | -1,718.2 | -68.3 | 110.7 |
| 2.6 | 1.4 | 2.1 | 1.1 | 2.1 | 1.3 | 1.6 | 0.2 | 4.0 | -2.2 | 0.8 | 0.2 |
| 1.6 | 0.7 | 2.6 | 1.5 | 1.6 | 0.0 | 1.1 | 0.2 | 3.3 | -2.5 | 0.4 | 0.3 |
| Financial Year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 24.7 | 22.1 | -8.6 | 18.9 | 44.2 | 6.0 | 2.8 | 41.4 | 14.2 |
| 49 | 61 | 74 | 68 | 81 | 119 | 124 | 132 | 183 | 208 |
Operating Profit Operating ProfitCr |
| 6.2 | 7.0 | 6.9 | 7.0 | 6.8 | 5.1 | 6.3 | 3.4 | 4.9 | 5.3 |
Other Income Other IncomeCr | 0 | 0 | 0 | 0 | 1 | 1 | 0 | -2 | 1 | 0 |
Interest Expense Interest ExpenseCr | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 7 | 8 | 8 |
Depreciation DepreciationCr | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 3 |
| 1 | 2 | 2 | 2 | 3 | 3 | 3 | 0 | 0 | 7 |
| 0 | 0 | 1 | 1 | 1 | 1 | 1 | -3 | 1 | 3 |
|
| | 117.0 | -2.3 | -19.9 | 23.0 | 18.2 | -1.7 | 54.0 | -128.1 | 231.1 |
| 1.6 | 2.7 | 2.2 | 1.9 | 2.0 | 1.6 | 1.5 | 2.2 | -0.4 | 0.5 |
| 2.1 | 4.6 | 3.4 | 2.7 | 3.4 | 3.1 | 1.1 | 3.5 | -2.1 | 0.7 |
| Financial Year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Equity Capital Equity CapitalCr | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 7 | 8 |
| 0 | 2 | 10 | 12 | 13 | 24 | 26 | 32 | 41 |
Current Liabilities Current LiabilitiesCr | 26 | 33 | 38 | 35 | 45 | 55 | 67 | 92 | 122 |
Non Current Liabilities Non Current LiabilitiesCr | 8 | 9 | 8 | 11 | 15 | 21 | 33 | 31 | 29 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 26 | 34 | 48 | 46 | 56 | 72 | 67 | 106 | 123 |
Non Current Assets Non Current AssetsCr | 12 | 14 | 14 | 17 | 22 | 41 | 70 | 69 | 85 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 3 | -2 | 5 | -4 | 0 | 17 | -13 | 11 |
Investing Cash Flow Investing Cash FlowCr | -2 | -1 | -4 | -6 | -20 | -38 | -1 | 2 |
Financing Cash Flow Financing Cash FlowCr | -1 | 5 | -2 | 10 | 27 | 17 | 14 | -3 |
|
Free Cash Flow Free Cash FlowCr | 1 | -3 | 1 | -10 | -12 | -22 | -13 | -9 |
| 188.0 | -91.3 | 330.1 | -222.0 | -2.0 | 834.7 | -410.6 | -1,266.6 |
CFO To EBITDA CFO To EBITDA% | 73.0 | -28.8 | 89.6 | -64.0 | -0.6 | 196.6 | -270.1 | 115.0 |
| Financial Year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 34 | 31 | 23 | 71 | 52 | 73 | 88 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 19.4 | 22.5 | 13.7 | 35.1 | 26.4 | 23.9 | 0.0 |
Price To Sales Price To Sales | 0.0 | 0.0 | 0.4 | 0.4 | 0.3 | 0.6 | 0.4 | 0.5 | 0.5 |
Price To Book Price To Book | 0.0 | 0.0 | 2.2 | 1.9 | 1.3 | 2.3 | 1.6 | 1.9 | 1.8 |
| 3.4 | 3.2 | 8.1 | 9.4 | 9.2 | 16.9 | 11.0 | 26.1 | 13.4 |
Profitability Ratios Profitability Ratios |
| 16.7 | 17.2 | 17.3 | 18.4 | 18.6 | 16.7 | 17.9 | 22.1 | 24.0 |
| 6.2 | 7.0 | 6.9 | 7.0 | 6.8 | 5.1 | 6.3 | 3.4 | 4.9 |
| 1.6 | 2.7 | 2.2 | 1.9 | 2.0 | 1.6 | 1.5 | 2.2 | -0.4 |
| 19.4 | 19.8 | 16.5 | 12.9 | 10.7 | 7.7 | 9.2 | 7.4 | 8.0 |
| 19.1 | 30.0 | 11.2 | 8.2 | 9.2 | 6.5 | 6.2 | 7.7 | -1.8 |
| 2.1 | 3.7 | 2.8 | 2.2 | 2.2 | 1.8 | 1.4 | 1.7 | -0.4 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
Ambani Orgochem Limited (formerly **Ambani Organics Limited**) is a specialized manufacturer, processor, and exporter of water-based specialty chemicals with over **three decades** of industrial expertise. The company operates as a single business segment under **AS 17**, focusing on high-performance solutions for diverse industrial applications. By leveraging the global **"China +1"** strategy and India’s **Atmanirbhar Bharat** initiative, the company has positioned itself as a critical player in the specialty chemicals hub of India.
---
### **Diversified Product Portfolio & Industrial Applications**
The company manufactures a wide range of specialty chemicals designed to enhance efficiency and performance across several high-growth sectors. The portfolio is centered on cost-effective, sustainable development.
| Segment | Primary Applications & Products |
| :--- | :--- |
| **Textiles** | Textile Auxiliaries, Binders, Emulsions, and finishing agents. |
| **Paints & Coatings** | Paint Dryers, Metal Octoates, and additives for decorative/industrial use. |
| **Pharma & Personal Care** | Salicylic Acid, Salicylic Derivatives, and Organic Peroxides. |
| **Building Materials** | Construction chemicals and specialized Adhesives. |
| **Paper & Carpet** | Processing chemicals for pulp, paper manufacturing, and carpet backing. |
| **Performance Chemicals** | Resins and additives for the **FRP (Fiber Reinforced Plastic)** industry. |
---
### **Manufacturing Infrastructure & Quality Standards**
The company has scaled its production capacity from **700 tons in 1996** to **24,000 tons** as of the latest expansion phase.
* **Dahej Facility (Gujarat):** Located in the Dahej Industrial Area, this "state-of-the-art" unit is the cornerstone of the company's expansion. Following a major fire in **February 2024**, the facility underwent a **10-month** re-establishment process. Trial production resumed in **February 2025**, with full commercial operations commencing on **February 15, 2025**.
* **Tarapur Facility (Maharashtra):** This site houses primary manufacturing units and a dedicated **In-house R&D Centre** (Plots N-42, N-44, and N-55, MIDC Tarapur).
* **Certifications:** The company maintains **ISO 9001:2015**, **ISO 14001:2015**, and **ISO 45001:2018** certifications. Its textile chemicals are further validated by **GOTS** (Global Organic Textiles Standards) and **ZDHC** (Zero Discharge of Hazardous Chemicals) compliance.
---
### **Financial Performance & Operational Turnaround**
Ambani Orgochem has demonstrated a sharp recovery in **H1 FY26**, following a period of operational disruption. The company is successfully transitioning toward a higher mix of **value-added Salicylates and Peroxide derivatives**.
#### **H1 FY26 Financial Highlights (Consolidated)**
| Particulars (₹ Lakhs) | H1 FY26 | H1 FY25 | YoY Growth |
| :--- | :--- | :--- | :--- |
| **Revenue** | **10,915.18** | **8,175.46** | **33.51%** |
| **EBITDA** | **791.57** | **447.79** | **76.77%** |
| **EBITDA Margin** | **7.16%** | **5.46%** | **+170 bps** |
| **Net Profit (PAT)** | **19.07** | **(178.48)** | **Turnaround** |
#### **Revenue Mix and Historical Context**
* **Export Pivot:** There has been a significant shift toward international markets. In **FY24**, **Exports** surged to **₹141.95 crore** (up from **₹38.56 crore** in FY23), while domestic sales moderated.
* **FY25 Momentum:** The company achieved a **42% growth in turnover** for the full year FY25. **EBITDA** increased by **133%** to **₹9.25 crore**, though high finance costs limited the **PBT to ₹35.93 lakhs**.
* **Tarapur Resilience:** The Tarapur units achieved a turnover of **₹100.92 crore** in **H2 FY25**, a **51% growth** over the previous year.
---
### **Strategic Growth & Capital Allocation**
The management, led by **Mr. Rakesh H. Shah** (MD) and **Mrs. Apooni R. Shah** (WTD), is executing a strategy focused on capacity utilization and financial deleveraging.
* **Product Value Chain:** Moving beyond basic chemicals into complex **Salicylates** and **Peroxide derivative** variants to capture higher margins.
* **R&D Investment:** Strengthening facilities to develop customer-specific solutions for the **100 Smart Cities** initiative and the broader construction sector.
* **Capital Raising:**
* **Convertible Warrants (Dec 2024):** Approved up to **1,260,000** warrants at **₹90** each (Premium of **₹80**), raising approximately **₹11.34 Crores**.
* **Equity Allotment (Nov 2024):** Allotted **600,000 Equity Shares** following warrant conversion.
* **Reserve Strengthening:** In FY25, the company forfeited **₹5.80 crore** (25% upfront money) from **2,900,000 warrants** due to non-payment of the balance by subscribers, transferring the amount to **General Reserves**.
* **Efficiency Targets:** Active focus on reducing **finance costs**, rationalizing administrative expenditure, and improving the **working capital cycle**.
---
### **Risk Management & Recovery Status**
The company has navigated significant headwinds, most notably the **February 2024 Dahej fire**.
#### **Insurance Recovery (Dahej Incident)**
| Claim Type | Amount / Status |
| :--- | :--- |
| **Material Damage (PPE & Inventory)** | **₹20.49 Crore** received in **March 2025**. |
| **Loss of Profit** | Claim is **under process** as of **October 2025**. |
#### **Key Risk Factors**
* **Competitive Landscape:** The market is highly fragmented. Larger competitors may have superior **financial and R&D resources**, while the unorganized sector and **cheap imports** pressure pricing.
* **Macroeconomic Sensitivity:** Slower GDP growth or high interest rates could impact the **home improvement** and **construction** sectors.
* **Geopolitical Volatility:** Ongoing tensions in the Asian region create risks for **input prices**, **logistics**, and **supply chain stability**.
* **Legal & Estimation Risks:** Auditors note inherent uncertainties in estimating **Loss of Profit** claims. While management views pending litigation receivables as **"good and recoverable,"** these remain under monitor.
---
### **Corporate Structure**
Ambani Orgochem Limited operates with two key subsidiaries:
1. **Omega Woven Mills Private Limited**
2. **Om Maruti Glasswool & Wirenetting Products Private Limited**
The company’s **Authorised Share Capital** stands at **₹20.00 crore**, consisting of **1.30 crore Equity Shares** and **70 lakh Preference Shares** (Face Value **₹10**).